Skinvisible announces article on transdermal obesity formulation development

Skinvisible announced the publication of an article highlighting the Company’s innovative development of transdermal delivery of glucose-controlling agents using its proprietary delivery system Invisicare. The article, titled “Advancements in Transdermal Delivery Systems: A Focus on Invisicare Technology for Obesity Treatment,” was published in Drug Development & Delivery in its October issue. “The data published in Drug Development & Delivery demonstrates that our Invisicare based transdermal formulation of a GLP-1 active, showed significant transdermal delivery over a six-hour period,” said James Roszell, PhD, Skinvisible’s Head of R&D. “The Company continues to work on other GLP-1 agonists and CB-1 antagonists, as these findings suggest that our Invisicare transdermal platform could open the door to a non-invasive approach to delivering obesity and/or glucose-controlling agents.” Key benefits of Invisicare transdermal obesity formulations: Invisicare technology; a polymer delivery vehicle does not require a patch or needles for transdermal delivery; The Company previously announced it has filed two provisional patent applications covering formulations that leverage Invisicare for the transdermal administration of glucose-controlling agents; The results from Franz cell diffusion studies demonstrated compelling results: GLP-1 drug formulated with Invisicare showed a 99.6% penetration over 6 hours; CB-1 antagonists formulated with Invisicare, showed a 62% penetration over 6 hours; Formulations showed a sustained drug delivery over time, with no initial spike; This data opens up exciting opportunities compelling the Company to expand its portfolio of obesity-targeting formulations with other active ingredients; Other small molecules, both in the obesity space and other indications, have the potential to be delivered by Invisicare technology. Skinvisible is actively seeking strategic partnerships with pharmaceutical and biotech companies to bring the first transdermal obesity therapies to market and explore broader applications of its delivery platform.